Research Analysts Issue Forecasts for Coya Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:COYA)

Coya Therapeutics, Inc. (NASDAQ:COYA) – Equities researchers at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for Coya Therapeutics in a note issued to investors on Monday, September 16th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.41) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2024 earnings at ($0.43) EPS, FY2024 earnings at ($1.38) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($1.48) EPS.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.19) earnings per share for the quarter. The business had revenue of $3.43 million for the quarter.

Several other equities analysts also recently commented on COYA. Rodman & Renshaw assumed coverage on shares of Coya Therapeutics in a report on Thursday, June 13th. They issued a “buy” rating and a $18.00 target price on the stock. Chardan Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Wednesday, June 5th.

Coya Therapeutics Stock Down 1.3 %

NASDAQ:COYA opened at $6.06 on Thursday. The business’s 50-day simple moving average is $6.32 and its two-hundred day simple moving average is $7.56. Coya Therapeutics has a 52 week low of $3.21 and a 52 week high of $10.69. The stock has a market cap of $88.59 million, a PE ratio of -7.13 and a beta of 0.58.

Institutional Trading of Coya Therapeutics

Several large investors have recently bought and sold shares of COYA. Gilbert & Cook Inc. purchased a new stake in Coya Therapeutics in the 2nd quarter worth approximately $61,000. Renaissance Technologies LLC purchased a new position in Coya Therapeutics in the second quarter worth approximately $101,000. Vanguard Group Inc. grew its holdings in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares during the period. AIGH Capital Management LLC increased its position in shares of Coya Therapeutics by 92.6% during the fourth quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock valued at $7,381,000 after acquiring an additional 496,183 shares during the last quarter. Finally, Greenlight Capital Inc. raised its holdings in shares of Coya Therapeutics by 172.2% in the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock valued at $9,441,000 after buying an additional 805,959 shares during the period. Hedge funds and other institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.